Novartis ups sales growth and margins in 2024

31 January 2025

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its cardiovascular and immunology products.

The Swiss pharma giant said net sales rose 16% in the fourth quarter to $13.2 billion, contributing to full-year revenue of $50.3 billion. Core operating income increased 29% to $4.9 billion, while net income climbed 6% to $2.8 billion, and core earnings per share (EPS) grew 33% to $1.98.

Entresto (sacubitril/valsartan) saw 34% growth in the quarter, supported by higher adoption in heart failure treatment, while immunology drugs Cosentyx (secukinumab) and Kesimpta (ofatumumab) grew 24% and 49% respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical